Deutsche Bank Maintains a 'Buy' on Amylin Pharmaceuticals (AMLN); Thinking Long-Term: Bydureon a Likely Blockbuster
Tweet Send to a Friend
Deutsche Bank maintains a 'Buy' on Amylin Pharmaceuticals (Nasdaq: AMLN), PT $27.
Deutsche analyst says, "Amylin is awaiting approval of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Deutsche analyst says, "Amylin is awaiting approval of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
